Intrinsiqq
Agios Pharmaceuticals Inc. logo

Agios Pharmaceuticals Inc. Intrinsic Value

AGIO

Compare

Choose a model

Each card values Agios Pharmaceuticals a different way, shown at our starting inputs. Pick one to see and change how it works.

Set your assumptions

Agios Pharmaceuticals on revenue: sales per share grow and the stock trades at a normal price-to-sales multiple. For companies not yet profitable.

Years to project

Growth of revenue per share

Revenue per share; starts at its own recent growth

Exit P/S

Starts at its own median P/S over five years

Your desired return

Margin of safety

More

Your buy price

The expected return is measured from it; starts at today's price

How it's worked out

  1. Today's revenue per share

    Last twelve months

    $2.35

  2. Revenue in 2031

    Grows 30.0% a year for 5 years

    $8.74

  3. Price in 2031

    $8.74 × 15.0 P/S

    $131.15

  4. Worth today

    ÷ 1.10^5: your 10% a year, taken back out

    $81.43

  5. Fair value

    The most you can pay and still earn 10% a year

    $81.43

  6. Buy below

    Fair value minus your 25% margin of safety

    $61.08

Paying $27.60 instead gives 36.6% a year. Every rule is on the methodology page.

Outcome

What your assumptions give, and the path from today's price.

Fair value

$81.43

Expected return

36.6% a year

Future price, 2031

$131.15

Buy below

$61.08

Price 66% below fair valuePrice $27.60, at your 10% return

Projection

Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.

Agios Pharmaceuticals (AGIO) intrinsic value and fair value

The calculator grows one of Agios Pharmaceuticals's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for AGIO; this is analysis, not investment advice.

Frequently asked

What is Agios Pharmaceuticals's (AGIO) intrinsic value?+

With Intrinsiqq's starting inputs, Agios Pharmaceuticals's fair value is about $81.43 a share, based on its revenue per share. That assumes revenue per share of $2.35 grows about 30.0% a year for 5 years, the stock then trades at 15.0 times revenue, and you want a 10.0% yearly return. Every input can be changed on the page; the result is a model, not a forecast.

Is Agios Pharmaceuticals overvalued?+

At $27.60, the price is 66% below that fair value of $81.43, and buying at today's price would return about 36.6% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from SEC filings, not investment advice.

What growth does the Agios Pharmaceuticals valuation assume?+

Revenue per share grows about 30.0% a year to start, its own recent growth per share (three years for a company not yet profitable, five otherwise), capped at 20%. The exit multiple starts at its own median over five years.

What is a good margin of safety for Agios Pharmaceuticals?+

A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $61.08. Less predictable businesses deserve a wider cushion, or a higher desired return.

How the market compares: US profitability statistics

SourceFair value computed from the 10-Q filed 30 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.

Price from market data, last close as of 20 Nov 2026. Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AGIO

CompareIntrinsic value
ELTPElite Pharmaceuticals Inc.
$0.32+0.69%81
KPTIKaryopharm Therapeutics Inc.
$0.02-48.67%15
ZVRAZevra Therapeutics, Inc.
$8.76-3.42%83
HRTXHeron Therapeutics Inc.
$0.25-2.88%26
PGENPrecigen Inc.
$4.21+1.20%29
DAWNDay One Biopharmaceuticals, Inc.
No recent price10
SPRYArs Pharmaceuticals Inc
$2.96-11.90%40
GYREGyre Therapeutics Inc.
$4.21-6.86%18

Held by ETFs

AGIO is in 53 US ETFs. The largest of them, with AGIO's weight in each:

Spot a number that looks wrong? Check it in AGIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AGIO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.